Please login to the form below

Not currently logged in
Email:
Password:

alirocumab

This page shows the latest alirocumab news and features for those working in and with pharma, biotech and healthcare.

Sanofi, Regeneron offer price cut for cholesterol drug Praluent

Sanofi, Regeneron offer price cut for cholesterol drug Praluent

Praluent (alirocumab) to high-dose statins reduced cardiovascular events and all-cause mortality compared to statins alone.

Latest news

More from news
Approximately 10 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Sanofi has been adept in this area with its previous access to a PRV for Alirocumab for dyslipidaemia (in partnership with Regeneron who had originally purchased the PRV from Biomarin) for

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration

  • Pharma deals during November 2014 Pharma deals during November 2014

    In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9 inhibitor alirocumab, being developed in partnership with Sanofi.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics